Cytology specimens offer an effective alternative to formalin-fixed tissue as demonstrated by novel automated detection for ALK break-apart FISH testing and immunohistochemistry in lung adenocarcinoma

Cancer Cytopathology

Volumn 122, Issue 11, 2014, Pages 810-821

  Rosenblum, Frida ^a   Hutchinson, Lloyd M ^b   Garver, Joann ^b   Woda, Bruce ^b   Cosar, Ediz ^b   Kurian, Elizabeth M ^c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

ALK immunohistochemistry; anaplastic lymphoma kinase (ALK); crizotinib; fluorescence in situ hybridization (FISH); lung adenocarcinoma; lung cytology

Indexed keywords

ALCOHOL; ANAPLASTIC LYMPHOMA KINASE; FORMALDEHYDE; ALCOHOL DERIVATIVE; EPIDERMAL GROWTH FACTOR RECEPTOR; FIXATIVE; PROTEIN TYROSINE KINASE; RAS PROTEIN;

ADULT; AGED; ALK GENE; ANTIBODY DETECTION; ARTICLE; BRAF GENE; CELL STRUCTURE; CODON; CONTROLLED STUDY; CULTURE MEDIUM; CYTOLOGY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE MARKER; DNA FRAGMENTATION; EGFR GENE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GEL ELECTROPHORESIS; GENE REARRANGEMENT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; MOLECULAR DIAGNOSIS; NEEDLE BIOPSY; ONCOGENE; ONCOGENE K RAS; PILOT STUDY; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SPECTROPHOTOMETRY; VALIDATION PROCESS; ADENOCARCINOMA; CHEMISTRY; CYTODIAGNOSIS; GENETICS; LUNG NEOPLASMS; METABOLISM; MIDDLE AGED; MUTATION; PAPANICOLAOU TEST; PROCEDURES; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; TISSUE FIXATION; VERY ELDERLY; YOUNG ADULT;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ALCOHOLS; CYTODIAGNOSIS; FEMALE; FIXATIVES; FORMALDEHYDE; GENE REARRANGEMENT; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; PAPANICOLAOU TEST; RAS PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TISSUE FIXATION; YOUNG ADULT;

EID: 84920523850     PISSN: 1934662X     EISSN: 19346638     Source Type: Journal    
DOI: 10.1002/cncy.21467     Document Type: Article

References (55)

1. American Cancer Society. Cancer Facts and Figures. 2012. cancer.org/research/cancerfactsfigures/cancerfactsfigures/cancer-facts-figures-2012. Accessed June 18, 2014.
2. Siegel R, Naishadham D, Jemal A,. Cancer statistics, 2012. CA Cancer J Clin. 2012; 62: 10-29.
3. Kim L, Kim KH, Yoon YH, et al. Clinicopathologic and molecular characteristics of lung adenocarcinoma arising in young patients. J Korean Med Sci. 2012; 27: 1027-1036.
4. Normanno N, Rachiglio AM, Roma C, et al. Molecular diagnostics and personalized medicine in oncology: challenges and opportunities. J Cell Biochem. 2013; 114: 514-524.
5. Koivunen JP, Mermel C, Zejnullahu K, et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res. 2008; 14: 4275-4283.
6. Lindeman N, Cagle PT, Beasley MB, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Arch Pathol Lab Med. 2013; 137: 828-860.
7. Shaw AT, Yeap BY, Solomon BJ, et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol. 2011; 12: 1004-1012.
8. Abbott Laboratories. Vysis ALK Break Apart FISH Probe Kit [package insert]. Abbott Park, IL: Abbott Laboratories; 2011.
9. National Cancer Institute. FDA Approval for Crizotinib. cancer.gov/cancertopics/druginfo/fda-crizotinib. Accessed June 18, 2014.
10. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010; 363: 1693-1703.
11. Gandhi L, Janne PA,. Crizotinib for ALK-rearranged non-small cell lung cancer: a new targeted therapy for a new target. Clin Cancer Res. 2012; 18: 3737-3742.
12. Shaw AT, Solomon B,. Targeting anaplastic lymphoma kinase in lung cancer. Clin Cancer Res. 2011; 17: 2081-2086.
13. Christensen JG, Zou HY, Arango ME,. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol Cancer Ther. 2007; 6: 3314-3322.
14. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007; 448: 561-566.
15. Inamura K, Takeuchi K, Togashi Y, et al. EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset. Mod Pathol. 2009; 22: 508-515.
16. Zhang X, Zhang S, Yang X, et al. Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression. Mol Cancer. 2010; 9: 188.
17. Nishino M, Klepeis VE, Yeap BY, et al. Histologic and cytomorphologic features of ALK-rearranged lung adenocarcinomas. Mod Pathol. 2012; 25: 1462-1472.
18. Travis WD, Brambilla E, Noguchi M,. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 2011; 6: 244-285.
19. Rodig SJ, Mino-Kenudson M, Dacic S, et al. Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res. 2009; 15: 5216-5223.
20. Sasaki T, Rodig SJ, Chirieac LR, et al. The biology and treatment of EML4-ALK non-small cell lung cancer. Eur J Cancer. 2010; 46: 1773-1780.
21. Thunnissen E, Bubendorf L, Dietel M, et al. EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations. Virchows Arch. 2012; 461: 245-257.
22. Pirker R, Herth FJ, Kerr KM, et al. Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop. J Thorac Oncol. 2010; 5: 1706-1713.
23. Wallander ML, Geiersbach KB, Tripp SR, et al. Comparison of reverse transcription-polymerase chain reaction, immunohistochemistry, and fluorescence in situ hybridization methodologies for detection of echinoderm microtubule-associated proteinlike 4-anaplastic lymphoma kinase fusion-positive non-small cell lung carcinoma: implications for optimal clinical testing. Arch Pathol Lab Med. 2012; 136: 796-803.
24. Witt BL, Wallander ML, Layfield LJ, et al. Respiratory cytology in the era of molecular diagnostics: a review. Diagn Cytopathol. 2012; 40: 556-563.
25. Weickhardt AJ, Aisner DL, Franklin WA, et al. Diagnostic assays for identification of anaplastic lymphoma kinase-positive non-small cell lung cancer. Cancer. 2013; 119: 1467-1477.
26. Mino-Kenudson M, Chirieac LR, Law K, et al. A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry. Clin Cancer Res. 2010; 16: 1561-1571.
27. Minca EC, Lanigan CP, Reynolds JP, et al. ALK status testing in non-small-cell lung carcinoma by FISH on ThinPrep slides with cytology material. J Thorac Oncol. 2014; 9: 464-468.
28. Conklin CM, Craddock KJ, Have C, et al. Immunohistochemistry is a reliable screening tool for identification of ALK rearrangement in non-small-cell lung carcinoma and is antibody dependent. J Thorac Oncol. 2013; 8: 45-51.
29. Hutarew G, Hauser-Kronberger C, Strasser F, et al. Immunohistochemistry as a screening tool for ALK rearrangement in NSCLC: evaluation of 5 different ALK antibody clones and ALK FISH [published online ahead of print February 24, 2014]. Histopathology.
30. Lozano MD, Labiano T, Zudaire MI, et al. Usefulness of cytological samples (CS) for the assessment of ALK rearrangements in non-small cell lung cancer (NSCLC). ASCO Meeting Abstracts. 2012; 30 (suppl 15): e18008; J Clin Oncol 30, 2012 (suppl;abstr e18008).
31. Hasanovic A, Rekhtman N, Sigel CS, et al. Advances in fine needle aspiration cytology for the diagnosis of pulmonary carcinoma. Pathol Res Int. 2011; 2011: 897292.
32. Neat MJ, Foot NJ, Hicks A, et al. ALK rearrangements in EBUS-derived transbronchial needle aspiration cytology in lung cancer. Cytopathology. 2013; 24: 356-364.
33. Schmitt FC, Longatto-Filho A, Valent A, et al. Demystified molecular techniques in cytopathology practice. J Clin Pathol. 2008; 61: 258-267.
34. Sigel CS, Moreira AL, Travis WD, et al. Subtyping of non-small cell lung carcinoma: a comparison of small biopsy and cytology specimens. J Thorac Oncol. 2011; 6: 1849-1856.
35. Gomez Saez JM,. Diagnostic usefulness of tumor markers in the thyroid cytological samples extracted by fine-needle aspiration biopsy. Endocr Metab Immune Disord Drug Targets. 2010; 10: 47-56.
36. Betz BL, Dixon CA, Weigelin HC, et al. The use of stained cytologic direct smears for ALK gene rearrangement analysis of lung adenocarcinoma. Cancer (Cancer Cytopathol). 2013; 121: 489-499.
37. Proietti A, Ali G, Pelliccioni S, et al. Anaplastic lymphoma kinase gene rearrangements in cytological samples of non-small cell lung cancer: comparison with histological assessment. Cancer (Cancer Cytopathol). 2014; 122: 445-453.
38. Savic S, Bode B, Diebold J, et al. Detection of ALK-positive non-small-cell lung cancers on cytological specimens: high accuracy of immunocytochemistry with the 5A4 clone. J Thorac Oncol. 2013; 8: 1004-1011.
39. Cooper WA, O'Toole SA,. Detecting ALK gene rearrangements in lung cancer cytology specimens. J Cytol Histol. 2014; 5: 2.
40. Ventana,. Ventana ALK Scoring Interpretation Guide for Non-Small Cell Lung Carcinoma (NSCLC). Tucson, AZ: Ventana Medical Systems, Inc and Roche Diagnostics International Inc; 2012.
41. Van Dongen JJ, Langerak AW, Bruggemann M, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia. 2003; 17: 2257-2317.
42. Cornejo KM, Hutchinson L, Deng A, et al. BRAF/KRAS gene sequencing of sebaceous neoplasms after mismatch repair protein analysis. Hum Pathol. 2014; 45: 1213-1220.
43. Ladanyi M, Pao W,. Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond. Mod Pathol. 2008; 21 (suppl 2): S16-S22.
44. Hirsch F, Spreafico A, Novello S,. The prognostic and predictive role of histology in advanced non-small cell lung cancer: a literature review. J Thorac Oncol. 2008; 3: 1468-1481.
45. West H, Harpole D, Travis W,. Histologic considerations for individualized systemic therapy approaches for the management of non-small cell lung cancer. Chest. 2009; 136: 1112-1118.
46. h ed. Philadelphia: Lippincott Williams & Wilkins; 2008: 896-946.
47. Choi YL, Takeuchi K, Soda M, et al. Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer. Cancer Res. 2008; 68: 4971-4976.
48. Johnson JL, Pillai S, Chellappan SP,. Genetic and biochemical alterations in non-small cell lung cancer. Biochem Res Int. 2012; 2012: 940405.
49. Waynes MW, Sholl LM, Dietel M, et al. An international interpretation study using the ALK IHC antibody D5F3 and a sensitive detection kit demonstrates high concordance between ALK IHC and ALK FISH and between evaluators. J Thorac Oncol. 2014; 9: 631-638.
50. Sun JM, Choi YL, Won JK, et al. A dramatic response to crizotinib in a non-small-cell lung cancer patient with IHC-positive and FISH-negative ALK. J Thorac Oncol. 2012; 7: e36-e38.
51. Tanaka H, Hayashi A, Morimoto T. A case of lung adenocarcinoma harboring EGFR mutation and EML4-ALK fusion gene. BMC Cancer. 2012; 12: 558.
52. Gillespie JW, Best CJ, Bichsel VE, et al. Evaluation of non-formalin tissue fixation for molecular profiling studies. Am J Pathol. 2002; 160: 449-457.
53. Malapelle U, Bellevicine C, Zeppa P, et al. Cytology-based gene mutation tests to predict response to anti-epidermal growth factor receptor therapy: a review. Diagn Cytopathol. 2011; 39: 703-710.
54. Srinivasan M, Sedmak D, Jewell S,. Effect of fixatives and tissue processing on the content and integrity of nucleic acids. Am J Pathol. 2002; 161: 1961-1971.
55. Knoepp SM, Roh MH,. Ancillary techniques on direct-smear aspirate slides. Cancer (Cancer Cytopathol). 2013; 121: 120-128.